Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 184 participants.
Also called NCT02906709
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 184 participants
- Sponsor
- Registry
-
NCT02906709
-
- Other papers using this trial's data
- A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT02906709. Randomized; double masking; primary purpose treatment. Start 2016-10-17 (actual); primary completion 2018-08-21 (actual). Results posted on 2019-09-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Omarigliptin
- Intervention (Drug)
- Placebo
- Intervention (Biological)
- Insulin
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct02906709- Content hash
4f9c3a686437ce3c92bde6ea5969cbfff129c5e2e3c76dfb984a22f8d4c5ca2a